EBA proposes guidelines for initial margin model authorization
The European Banking Authority has published a consultation paper on draft guidelines for the authorization of initial margin models under Article 11(3) EMIR. These guidelines detail minimum information for applications and define changes triggering re-authorization. Comments are invited by June 17, 2026.
EMIR 3 tightens model authorization
Regulation (EU) 2024/2987 (EMIR 3) mandates prior authorization for initial margin (IM) models used as a risk-mitigation technique for OTC derivative contracts not cleared by a CCP.
This includes both proprietary models and 'pro forma models' like ISDA's Standard Initial Margin Model (ISDA SIMM).
EMIR 3 tasks the EBA with validating these pro forma models for the entire EU, a prerequisite for competent authorities to grant authorization.
The regulation sets tight deadlines for these proceedings: six months for new models and three months for changes to previously authorized models.
This framework necessitates close cooperation between counterparties, competent authorities, and the EBA to ensure a smooth and timely authorization process.
Streamlining the application process
The EBA's draft guidelines aim to ensure uniform application and authorization processes for risk-management procedures.
They detail the minimum information required in an application for IM model authorization and provide guidance on what constitutes a change that triggers the need for re-authorization.
Notification obligations for relevant aspects of authorization or withdrawal are also set out.
The EBA plans a gradual 18-month rollout, staggering application based on the significance of counterparties' OTC trading activities.
Clarity for complex derivatives
This consultation is crucial for standardizing a complex regulatory process, ensuring uniform application across the EU.
While the staggered rollout offers flexibility, the tight authorization timelines will still challenge counterparties.
Ultimately, clear guidelines are essential for effective risk mitigation in OTC derivatives.